Daniel Huang, MegaRobo founder and CEO (Bosch Presse)

Gold­man Sachs leads a $300M round in­to a Chi­na biotech uni­corn boast­ing of its AI/ro­bot­ics prowess

The pub­lic mar­kets may have turned in­to a killing zone for biotechs and a harsh en­vi­ron­ment for tech stocks gen­er­al­ly, but that doesn’t mean the big mon­ey has stopped flow­ing in­to some se­lect glob­al AI star­tups.

Gold­man Sachs took an un­usu­al turn in­to the field this week, lead­ing a $300 mil­lion round for a Bei­jing-based start­up boast­ing of its mus­cle pow­er on CRISPR gene edit­ing while promis­ing to use AI and ro­bot­ics to re­de­fine lab ef­fi­cien­cy in cre­at­ing new drugs with clients.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.